The Taiwanese continuous glucose monitoring (CGM) Market is projected to grow at a CAGR of 17.73% over the forecast period, increasing from US$9.034 million in 2025 to reach US$20.435 million by 2030.
Continuous glucose monitoring (CGM) is a wearable medical device designed to monitor continuously blood sugar levels. continuously, catering to It is used by individuals with both type 1 and type 2 diabetes. In Taiwan, the CGM market is experiencing significant growth, driven by various factors.
Key drivers include the growing prevalence of diabetes, a heightened awareness and acceptance of CGM technology, robust government support, and policy initiatives. Additionally, the increasing disposable income and a growing focus on healthcare contribute to the market's upward trajectory. CGM devices, like other innovative monitoring tools, play a pivotal role in transforming patient care. They empower "remote" patients, allowing them to leverage monitoring devices and wearable sensors, such as continuous glucose monitoring systems (CGMS).
These devices not only collect crucial healthcare data but also enable the transmission of this information to relatives and healthcare providers. This facilitates timely interventions, potentially reducing the need for hospital visits. Globally, MicroTech CGMS has proven instrumental in aiding thousands of patients through remote monitoring.
In Taiwan, numerous companies, such as Bionime, are making significant strides in the CGM market. In October 2023, Bionime Corporation received approval from the TFDA (Taiwan FDA). The iFree Continuous Glucose Monitoring System (iFree CGM) is for detecting glycemic trends and managing glucose levels. It can help to detect hyperglycemia and hypoglycemia. iFree CGM can benefit not only diabetes patients but also people who need it for glucose management.
The impaired glucose tolerance (IGT) estimates (20-79 y), the age-adjusted comparative prevalence of IGT in Taiwan was 11.5% in 2021, likely to be 12.4 % in 2030, and 12.8 % in 2045. Due to this, the CGM market in Taiwan is poised for immense growth, and capitalizing on these driving forces is imperative for sustained expansion. This strategic approach not only ensures market growth but also plays a vital role in enhancing diabetes management for thousands of individuals in Taiwan.
The prevalence of Type 2 diabetes in Taiwan has experienced a significant surge over the past few decades. This alarming increase is primarily attributed to unhealthy lifestyles characterized by diets high in sugar and fat, coupled with insufficient physical activity. In 2021, the number of individuals aged 20-79 with diabetes was 2,457.2 (in 1,000s), a figure projected to escalate to 2,979.4 (in 1,000s) by 2030, and 3,030.7 (in 1,000s) by 2045 as per estimates from the International Diabetes Federation.
While increased awareness and improved diagnostics have contributed to higher detection rates, the numbers are expected to rise further due to urbanization, an aging population, and persistently unhealthy lifestyles. Traditionally, diabetes management in Taiwan heavily relied on finger-prick glucometers. However, CGM Continuous Glucose Monitoring has emerged as a transformative tool, providing real-time glucose data and trend analysis. This not only facilitates better glycemic control but also enhances the overall quality of life for individuals managing diabetes.
The growing recognition of these advantages, coupled with marketing efforts by CGM manufacturers, is propelling the adoption of CGM technology in Taiwan. This shift in approach holds promise for improving diabetes management outcomes amidst the rising challenges posed by the escalating rates of Type 2 diabetes in the country.
In Taiwan, pharmacies are seen as a key instrument for improving healthcare coverage. Technology tools have been implemented in the pharmaceutical sector. Companies who participate in the "Beyond the Pills" campaign add digital platforms to their drug treatment programs to encourage follow-up and guarantee treatment continuation. One of the businesses utilizing the Beyond the Pills method to treat diabetes is Roche. MySugr is a digital platform used by the pharmaceutical business to control diabetes. To meet unmet requirements, Roche can do so by providing openly available patient solutions. It seeks to assist diabetics in improving their quality of life by helping them spend more time inside their optimum glucose target range.
The Taiwanese continuous glucose monitoring market is segmented by application into diabetes patients and critical patients. Taiwan’s market for CGM for diabetics has been expanding rapidly due to several factors. An aging population, altered eating patterns, and lifestyle changes have all contributed to the rising incidence of diabetes, which has increased demand for sophisticated glucose monitoring devices. For instance, according to the National Development Council, the number of elderly people is increasing rapidly in the country. In 2017, the number of elderly population was 3,268 thousand persons, which increased to 4,086 thousand people in 2022, and 4,297 thousand people in 2023., the number of elderly people increased to 4,297 thousand persons. Elderly people are at high risk of developing diseases such as diabetes. Hence, the rising number of the elderly population is anticipated to impact the market for continuous glucose monitoring in the projected period.
Many other factors impact the Taiwan market for CGM among diabetic patients. The adoption of CGM technology is impacted by the quality and accessibility of Taiwan’s healthcare infrastructure. T Economic factors, including GDP growth and healthcare spending, influence the purchasing power of consumers and healthcare providers. is influenced by economic factors, including GDP growth and healthcare spending. Additionally, the rising per capita income is also expected to impact the market positively in the projected period.
For instance, as per the Ministry of Foreign Affairs, Republic of China (Taiwan), the nominal GDP of Taiwan was US$653 billion in 2022. and As per the International Monetary Fund, the nominal GDP will increase to US$802.96 billion in 2024. Hence, the above factors are anticipated to influence the market for the diabetes patient segment in the CGM market. Moreover, the increasing number of diabetes patients is anticipated to propel the market for continuous glucose monitoring (CGM) for diabetes patients in the projected period.
The market leaders for the Taiwan Continuous Glucose Monitoring Market are Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Inc., Tandem Diabetes Care, Inc., ARKRAY Inc., Taidoc Technology Corporation, Bionime Corporation, Novo Nordisk A/S
The key players in the market implement growth strategies such as product launches, mergers, acquisitions, etc. to gain a competitive advantage over their competitors. For Instance,
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Taiwan Continuous Glucose Monitoring (CGM) Market Size in 2025 | US$9.034 million |
| Taiwan Continuous Glucose Monitoring (CGM) Market Size in 2030 | US$20.435 million |
| Growth Rate | CAGR of 17.73% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Million |
| Segmentation |
|
| List of Major Companies in Taiwan Continuous Glucose Monitoring (CGM) Market |
|
| Customization Scope | Free report customization with purchase |